XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

The Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.

Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.

Monteverde & Associates PC, a class action securities firm, has announced investigations into Miluna Acquisition Corp. (MMTX) regarding its merger with CADV Ventures S.A., as well as investigations into XOMA Royalty Corporation (XOMA) and Helix Energy Solutions Group, Inc. (HLX). The firm is seeking shareholders with concerns about potential fairness issues in these transactions.

Ligand Pharmaceuticals announced it will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. The acquisition expands Ligand's royalty portfolio to over 200 assets and adds seven commercial products. Ligand raised its 2026 adjusted EPS guidance to $8.50-$9.50 and expects the transaction to be accretive by $1.50 per share in 2027. The deal is expected to close in Q3 2026.

XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about April 15, 2026, to shareholders of record as of April 2, 2026.

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

XOMA Royalty Corporation successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash plus one contingent value right. Approximately 70% of Generation Bio's outstanding shares were validly tendered by the February 6, 2026 expiration date, satisfying the minimum tender condition. Following the acquisition, Generation Bio became a wholly owned subsidiary of XOMA Royalty and ceased trading on Nasdaq.